Abarceo Pharma
Biotechnology ResearchView the employees at
Abarceo Pharma-
Kishan Bellamkonda, PhD Highly experienced researcher with expertise in gene editing, CRISPR-Cas9, FACS, cancer immunology, and cell & molecular biology. Looking for new opportunities.
-
Lund, Skåne County, Sweden
-
Top 5%
Ruchi Jain Principle Scientist at Abarceo Pharma-
Rising Star
Annie George Chandy Innovation Manager Lund University-
Greater Malmö Metropolitan Area
-
Top 10%
Kristian Hansen CEO at Abarceo Pharma AB and Founder of Zelandia Life Science R&D Consulting-
Slangerup, Capital Region, Denmark
-
Rising Star
Cornelia Nilsson Molecular Biology Student at Lund University-
Lund, Skåne County, Sweden
-
Rising Star
Overview
Abarceo is a preclinical stage company, a spinout of Lund University Diabetes Center. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
-